Influence of transcatheter arterial embolization on symptom distress and fatigue in liver cancer patients

doi:10.4251/wjgo.v16.i3.810

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1632)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-4) series.

Item

Count

PDF

WORD

HTML

946

Tables (1-4)

161

Sum=1163

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

338

Sum=404

Mar 15, 2024 (publication date) through Dec 25, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Mar 15, 2024; 16(3): 810-818
Published online Mar 15, 2024. doi: 10.4251/wjgo.v16.i3.810

Influence of transcatheter arterial embolization on symptom distress and fatigue in liver cancer patients

Xu-Min Yang, Xu-Yan Yang, Xin-Yu Wang, Yue-Xia Gu

Xu-Min Yang, Xu-Yan Yang, Department of Nursing, The First Affiliated Hospital of Naval Medical University (Changhai Hospital), Shanghai 200433, China

Xin-Yu Wang, Department of Thyroid, Breast and Vascular Surgery, Shanghai Fourth People’s Hospital Affiliated to Tongji University School of Medicine, Shanghai 200434, China

Yue-Xia Gu, Department of Nursing, Shanghai Fourth People’s Hospital Affiliated to Tongji University School of Medicine, Shanghai 200434, China

Author contributions: Gu YX and Yang XM contributed equally in analysis of the data and writing of the manuscript; Wang XY and Yang XY collected the data and corrected the paper; all authors have read and approved the final manuscript.

Institutional review board statement: The study was reviewed and approved by the Shanghai Fourth People’s Hospital Institutional Review Board (approval No. 2022108-001).

Informed consent statement: All patients provided informed consent for the surgical procedures.

Conflict-of-interest statement: The authors declare no conflicts of interest.

Data sharing statement: No additional data are available.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Yue-Xia Gu, MBBS, Chief Nurse, Department of Nursing, Shanghai Fourth People’s Hospital Affiliated to Tongji University School of Medicine, No. 1279 Sanmen Road, Hongkou District, Shanghai 200434, China. shdsyy_guyuexia@163.com

Received: September 26, 2023
Peer-review started: September 26, 2023
First decision: December 5, 2023
Revised: December 22, 2023
Accepted: February 7, 2024
Article in press: February 7, 2024
Published online: March 15, 2024
Processing time: 167 Days and 21.1 Hours

ARTICLE HIGHLIGHTS

Research background

Hepatocellular carcinoma (HCC) ranks as the fifth most common cancer globally and is a major contributor to cancer-related mortality. Surgical treatment remains pivotal, but late-stage diagnosis limits its applicability. Transcatheter arterial embolization (TAE) is an essential intervention for unresectable HCC, yet its impact on patient well-being requires further exploration.

Research motivation

Despite the significance of TAE in HCC management, the associated symptom distress and fatigue remain inadequately understood. A comprehensive investigation of symptom distress and fatigue following TAE is essential to enhance patient care and outcomes.

Research objectives

To assess symptom distress and fatigue in liver cancer patients undergoing TAE. To identify factors influencing post-TAE fatigue. To contribute evidence-based insights for personalized symptom management strategies.

Research methods

We used a cross-sectional design and purposive sampling to enroll liver cancer patients who underwent TAE. We used questionnaires to collect data on symptom distress and fatigue. We analyzed the data using statistical methods to reveal correlations and predictors.

Research results

TAE significantly reduced symptom distress and fatigue levels post-treatment. Commonly reported symptoms included pain, fatigue, insomnia, fever and abdominal discomfort. Marital status, family support, physical function, age, and symptom distress were identified as predictors of post-TAE fatigue.

Research conclusions

TAE plays a crucial role in managing unresectable HCC, with notable benefits in symptom distress and fatigue reduction. Personalized symptom management strategies should be tailored to individual patient profiles. Patient education is vital to prepare them for post-TAE symptoms and optimize their wellbeing.

Research perspectives

Future studies should focus on long-term follow-up to evaluate the sustained effects of TAE on symptom distress and fatigue. Exploring interventions to further mitigate symptom distress and fatigue in post-TAE patients. Continual research will enhance the understanding and management of symptom-related issues in liver cancer patients, improving their overall quality of life.